108 related articles for article (PubMed ID: 19816912)
1. Factors associated with response to calcineurin inhibitors in myasthenia gravis.
Nagane Y; Suzuki S; Suzuki N; Utsugisawa K
Muscle Nerve; 2010 Feb; 41(2):212-8. PubMed ID: 19816912
[TBL] [Abstract][Full Text] [Related]
2. Classification of myasthenia gravis based on autoantibody status.
Suzuki S; Utsugisawa K; Nagane Y; Satoh T; Terayama Y; Suzuki N; Kuwana M
Arch Neurol; 2007 Aug; 64(8):1121-4. PubMed ID: 17698702
[TBL] [Abstract][Full Text] [Related]
3. Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients.
Tanaka S; Nakajima K; Hirano T; Oka K; Saito T; Wakata N
J Pharm Pharmacol; 2008 Oct; 60(10):1341-6. PubMed ID: 18812027
[TBL] [Abstract][Full Text] [Related]
4. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis.
Suzuki S; Satoh T; Yasuoka H; Hamaguchi Y; Tanaka K; Kawakami Y; Suzuki N; Kuwana M
J Neuroimmunol; 2005 Dec; 170(1-2):141-9. PubMed ID: 16182377
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
6. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
9. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of tacrolimus on myasthenia gravis with thymoma.
Mitsui T; Kunishige M; Ichimiya M; Shichijo K; Endo I; Matsumoto T
Neurologist; 2007 Mar; 13(2):83-6. PubMed ID: 17351528
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
12. Multifocal paraneoplastic cortical encephalitis associated with myasthenia gravis and thymoma.
Hammoud K; Kandimala G; Warnack W; Vernino S
Arch Neurol; 2009 Nov; 66(11):1407-9. PubMed ID: 19901174
[TBL] [Abstract][Full Text] [Related]
13. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
14. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
Sekine Y; Kawaguchi N; Hamada C; Sekiguchi H; Yasufuku K; Iyoda A; Shibuya K; Fujisawa T
Eur J Cardiothorac Surg; 2006 Jun; 29(6):908-13. PubMed ID: 16675232
[TBL] [Abstract][Full Text] [Related]
15. [Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
Nakane S
Rinsho Shinkeigaku; 2013; 53(11):1309-11. PubMed ID: 24291970
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
Furukawa Y; Yoshikawa H; Iwasa K; Yamada M
J Neuroimmunol; 2008 Mar; 195(1-2):108-15. PubMed ID: 18262659
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
19. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.
Pascuzzi RM; Coslett HB; Johns TR
Ann Neurol; 1984 Mar; 15(3):291-8. PubMed ID: 6721451
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
